Drug intelligence / Profile preview

ochromycinone

Development stage
Phase 2
Lead developer
Kochi University of Technology
Modality
Small Molecules
Administration
Topical
01

Overview

Ochromycinone, also widely known by the code name STA-21, is a natural angucyclinone antibiotic and a small molecule inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathway. Originally isolated from various *Streptomyces* species, such as *Streptomyces ochraceus*, it possesses a characteristic tetracyclic benz[a]anthracene skeleton. Ochromycinone functions by specifically binding to the SH2 domain of STAT3, which prevents its dimerization and subsequent DNA binding. This inhibition disrupts the expression of genes involved in cell proliferation, survival, and inflammation. Due to the critical role of STAT3 in the pathogenesis of inflammatory diseases and various malignancies, ochromycinone has been investigated for its therapeutic potential in treating psoriasis and certain cancers. Clinical research has included pilot studies evaluating its efficacy as a topical treatment for psoriatic lesions.

Other names
ochromycinoneSTA 21STA21STA-21(8R,9S)-8,9-dihydroxy-1-methyl-8,9-dihydrotetraphene-7,12-dione
02

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on ochromycinone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ochromycinone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call